The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
HONG KONG, June 29, 2026 /PRNewswire/ -- EACON Group Co., Ltd. ("EACON", Stock Code: 07687.HK) launched the global offering of its H-shares today, marking...
JINCHANG, China, June 29, 2026 /PRNewswire/ -- The low-carbon development case Factor Empowerment, Green Revitalization of Nickel Capital: Practical Application of City-Zero Carbon Park-Enterprise Three-level...
SYDNEY, June 29, 2026 /PRNewswire/ -- Temu has signed up to a voluntary pledge administered by the Australian Competition and Consumer Commission (ACCC) to...
